Murphy Middleton Hinkle & Parker’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $461K | Hold |
8,007
| – | – | 0.19% | 100 |
|
|
2026
Q1 | $486K | Buy |
+8,007
| New | +$467K | 0.23% | 94 |
|
|
2025
Q4 | – | Sell |
-8,207
| Closed | -$370K | – | 143 |
|
|
2025
Q3 | $370K | Buy |
8,207
+62
| +0.8% | +$2.9K | 0.18% | 105 |
|
|
2025
Q2 | $497K | Hold |
8,145
| – | – | 0.28% | 90 |
|
|
2025
Q1 | $497K | Hold |
8,145
| – | – | 0.28% | 90 |
|
|
2024
Q4 | $461K | Hold |
8,145
| – | – | 0.26% | 94 |
|
|
2024
Q3 | $421K | Sell |
8,145
-333
| -4% | -$15.6K | 0.23% | 101 |
|
|
2024
Q2 | $352K | Hold |
8,478
| – | – | 0.2% | 106 |
|
|
2024
Q1 | $460K | Sell |
8,478
-179
| -2% | -$9.12K | 0.27% | 96 |
|
|
2023
Q4 | $444K | Hold |
8,657
| – | – | 0.27% | 90 |
|
|
2023
Q3 | $502K | Hold |
8,657
| – | – | 0.32% | 82 |
|
|
2023
Q2 | $554K | Hold |
8,657
| – | – | 0.35% | 82 |
|
|
2023
Q1 | $600K | Buy |
8,657
+333
| +4% | +$23.5K | 0.37% | 79 |
|
|
2022
Q4 | $599K | Hold |
8,324
| – | – | 0.38% | 77 |
|
|
2022
Q3 | $592K | Buy |
8,324
+3
| +0% | +$218 | 0.41% | 76 |
|
|
2022
Q2 | $641K | Hold |
8,321
| – | – | 0.42% | 78 |
|
|
2022
Q1 | $608K | Sell |
8,321
-60
| -0.7% | -$4.03K | 0.33% | 85 |
|
|
2021
Q4 | $523K | Hold |
8,381
| – | – | 0.28% | 89 |
|
|
2021
Q3 | $496K | Hold |
8,381
| – | – | 0.29% | 91 |
|
|
2021
Q2 | $560K | Buy |
8,381
+134
| +2% | +$8.74K | 0.31% | 87 |
|
|
2021
Q1 | $521K | Hold |
8,247
| – | – | 0.3% | 87 |
|
|
2020
Q4 | $512K | Sell |
8,247
-460
| -5% | -$28.3K | 0.34% | 82 |
|
|
2020
Q3 | $525K | Hold |
8,707
| – | – | 0.38% | 79 |
|
|
2020
Q2 | $512K | Buy |
8,707
+9
| +0.1% | +$538 | 0.38% | 81 |
|
|
2020
Q1 | $485K | Sell |
8,698
-115
| -1% | -$7.03K | 0.43% | 73 |
|
|
2019
Q4 | $566K | Buy |
8,813
+1,680
| +24% | +$96.2K | 0.38% | 76 |
|
|
2019
Q3 | $362K | Hold |
7,133
| – | – | 0.26% | 92 |
|
|
2019
Q2 | $323K | Buy |
7,133
+175
| +3% | +$8.15K | 0.23% | 99 |
|
|
2019
Q1 | $332K | Hold |
6,958
| – | – | 0.23% | 100 |
|
|
2018
Q4 | $362K | Hold |
6,958
| – | – | 0.28% | 90 |
|
|
2018
Q3 | $432K | Buy |
6,958
+200
| +3% | +$11.9K | 0.31% | 87 |
|
|
2018
Q2 | $374K | Sell |
6,758
-48
| -0.7% | -$2.59K | 0.28% | 91 |
|
|
2018
Q1 | $430K | Sell |
6,806
-115
| -2% | -$7.4K | 0.33% | 80 |
|
|
2017
Q4 | $424K | Buy |
+6,921
| New | +$433K | 0.32% | 81 |
|
Other funds holding BMY
Murphy Middleton Hinkle & Parker's BMY Position: Q2 2026 in Review
Murphy Middleton Hinkle & Parker held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 8,007 shares worth $461K. The position accounts for 0.19% of the portfolio, ranked #100.
Murphy Middleton Hinkle & Parker first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. The position peaked at $641K in Q2 2022. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Murphy Middleton Hinkle & Parker held 8,007 shares of Bristol-Myers Squibb worth $461K as of Q2 2026.
- Murphy Middleton Hinkle & Parker left its Bristol-Myers Squibb share count unchanged in Q2 2026.
- Bristol-Myers Squibb made up 0.19% of Murphy Middleton Hinkle & Parker's portfolio in Q2 2026, its #100 holding.
- Murphy Middleton Hinkle & Parker first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
- Murphy Middleton Hinkle & Parker's Bristol-Myers Squibb position peaked at $641K in Q2 2022.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Murphy Middleton Hinkle & Parker's 13F filing for Q2 2026, filed 14 Jul 2026.